Introduction {#s0005}
============

Acne vulgaris (AV) is a disease of the pilosebaceous unit that causes noninflammatory lesions (open and closed comedones), inflammatory lesions (papules, pustules, and nodules), and varying degrees of scarring. AV is an extremely common condition with a lifetime prevalence of approximately 85% and occurs mostly during adolescence ([@bb0120]). AV can persist into adulthood, with a 50.9% prevalence rate of acne in women ages 20 to 29 years versus 26.3% in women ages 40 to 49 years ([@bb0230]). Female patients account for two thirds of visits made to dermatologists for acne, and one third of all dermatology office visits for acne are by women who are older than 25 years ([@bb1410]).

Acne leads to significant morbidity that is associated with residual scarring and psychological disturbances such as poor self-image, depression, and anxiety, which leads to a negative impact on quality of life ([@bb0245], [@bb1095], [@bb1205]). In one epidemiologic study by [@bb1410], 8.8% of patients with acne reported depression with women suffering from depression twice as often as men (10.6% vs. 5.3%), but this was unrelated to acne severity.

Pathogenesis {#s0010}
============

Four key pathogenic processes lead to the formation of acne lesions: alteration of follicular keratinization that leads to comedones; increased and altered sebum production under androgen control; follicular colonization by *Propionibacterium acnes*; and complex inflammatory mechanisms that involve both innate and acquired immunity ([@bb1405], [@bb1420]). Genetics (twin studies [@bb0105], family history of severe acne [@bb1390]), diet (glycemic index [@bb0575], [@bb0700], [@bb1225], [@bb1230], [@bb1235]), including chocolate ([@bb0455], [@bb0870]) and dairy consumption ([@bb0010], [@bb0015], [@bb0290]); and environmental factors (smoking [@bb0670], [@bb1150], occlusive cosmetics [@bb1050], occupational exposures [@bb1355]) also contribute to the pathogenesis of acne.

The pathogenesis of acne in adult women is particularly complex. Androgens play a major role ([@bb0505], [@bb0840], [@bb0845]), as evidenced by the response of acne in adult women to hormonal treatments, especially in the context of hyperandrogenism disorders such as polycystic ovary syndrome (PCOS) and the use of hormone-based therapies such as oral contraceptive and anti-androgen medications in women with normal androgen levels ([@bb0805]). In addition, the lack of acne in androgen-insensitive women ([@bb0565], [@bb1305]) and rising levels of dehydroepiandrosterone sulfate in association with the onset of acne in premenarchal girls and a subset of patients with PCOS also play a major role ([@bb0840], [@bb0190]). Androgens stimulate sebum production via androgen receptors on the sebaceous glands.

Clinical presentation {#s0015}
=====================

Acne in women can occur at any age and with varying degrees of severity. Female patients may more frequently develop lesions on the lower third of the face, especially on the chin and jawline ([@bb0610]). However, a more recent epidemiologic study by [@bb0330] suggests that this hormonal distribution may not be the most common clinical presentation of acne in adult women.

Acne lesions range from comedones ([Fig. 1](#f0005){ref-type="fig"}) to papules and pustules ([Fig. 2](#f0010){ref-type="fig"}), cysts, and/or nodules ([Fig. 3](#f0015){ref-type="fig"}). In one study of postadolescent acne, 85% of patients had mostly comedonal acne ([@bb0165]) with two subtypes identified as persistent and late-onset acne ([@bb1095]). Persistent acne, which is defined as acne that persists beyond adolescence into adulthood, accounts for 80% of cases in adult female patients ([@bb0535]). Late-onset acne is defined as acne that begins after the age of 25 years ([@bb0535], [@bb1095]). Women with signs of hyperandrogenism such as hirsutism or menstrual irregularities and those with true late-onset acne should be further evaluated for an underlying endocrine disorder such as PCOS.Figure 1Comedones with post-inflammatory hyperpigmentation.Courtesy of Bethanee Schlosser, MD, PhD.Figure 1Figure 2Inflammatory papules and pustules.Courtesy of Bethanee Schlosser, MD, PhD.Figure 2Figure 3Acne Nodules and Cysts.Courtesy of Bethanee Schlosser, MD, PhD.Figure 3

To date, there is no universally agreed-upon grading system for acne, and the grading systems used in clinical trials vary greatly ([@bb1420]). Acne grading systems should take into account the type and severity of the acne, number of lesions, anatomic location and the extent of the acne, patient quality of life and other psychosocial metrics, and scarring ([@bb1420]). [@bb1280] evaluated 18 global acne grading scales with grading methods that ranged from text descriptions, grades for number and type of lesions, grades for severity, grades for comedonal versus inflammatory acne to the use of standardizing photographs.

Two groups of grading scales exist including those that use quantitative measures such as lesion counts and numeric ranges and those that are based on qualitative descriptions. Quantitative scales include those that specify the number and type of primary acne lesions ([@bb0280], [@bb0510], [@bb1045]) and those that assign weights to lesion types to generate a severity index ([@bb0300], [@bb0790], [@bb0940]). Qualitative scales use adjectives such as few, some, and numerous to quantify lesions. There are also scales that solely use photographic templates of varying severity ([@bb0160], [@bb0990]).

Evaluation considerations {#s0020}
=========================

The evaluation of any patient with acne should include a thorough medical history and physical examination. Medications and supplement use, social history including tobacco and illicit drug use, menstrual history (i.e., age of menarche, regularity of menses, history of infertility), and prior/current acne treatments must be elucidated ([@bb0610]). A complete review of systems should be conducted to seek symptoms of hyperandrogenism or other endocrinology disorders.

Signs and symptoms of hyperandrogenism include acne, hirsutism, seborrhea, androgenetic alopecia, amenorrhea, oligomenorrhea, virilization, clitoromegaly, infertility, polycystic ovaries, increased muscle mass, and decreased breast size ([@bb0505], [@bb0805]). Of these, hirsutism is the most common manifestation of hyperandrogenism and 70% of women with hirsutism have hyperandrogenism ([@bb0830]). Hirsutism is highly associated with elevated serum levels of free testosterone. Given that hair removal may obscure a clinician recognition of hirsutism, patients should be asked about the nature and frequency of hair removal practices as well as the locations of hair overgrowth. If patients exhibit signs or symptoms of hyperandrogenism, a thorough endocrinologic work-up should be initiated.

The differential diagnosis of acne in adult female patients is detailed in [Table 1](#t0005){ref-type="table"}, along with distinguishing characteristics. In addition, underlying systemic causes for acne including hyperandrogenism should be assessed. Causes of drug-induced acne are detailed in [Table 2](#t0010){ref-type="table"}.Table 1Differential diagnosis of acne vulgarisTable 1Disease/conditionDifferentiating characteristicsAcne keloidalis nuchaeOften seen in black patients; lesions localized to the posterior neck; initially papules and pustules that may progress to confluent keloidsAcneiform eruptionsSecondary to systemic medications, topical corticosteroid medications, contrast dye, and cosmetic products; may be abrupt in onset and correlation with exposure; improvement with cessation of exposure (See [Table 2](#t0010){ref-type="table"} for agents that cause drug-induced acne)ChloracneComedones, pustules, and cysts that localize to the post-auricular area, axillae, and groin; history of exposure to halogenated aromatic hydrocarbons; patient may have other systemic manifestationsFavre-RacouchotOpen and closed comedones on periorbital and malar areas; no inflammatory lesions; patients are usually older with a history of significant sun exposureBacterial folliculitis (non-gram-negative)Erythematous papules and pustules that are follicularly-based; often affects trunk and extremitiesGram-negative folliculitisFrequently occurs in patients with acne who have been on long-term antibiotic medications; pustules and nodules; may also occur in HIV + patients, and after hot tub exposure; lesions may be cultured if acneiform lesions do not respond to typical antibiotic regimenLupus miliaris disseminatus facieiYellow/brown/red smooth papules in the periorbital and eyelid skin; biopsy shows caseating epithelioid granulomasMiliaWhite keratinaceous cysts; lesions are usually persistent; noninflammatoryPeriorificial dermatitisPapules and pustules in the periorificial distribution; often exacerbated by topical corticosteroid usePyoderma facialeRapid onset of erythema, abscesses, cysts, and possible sinus tracts, no comedonesRosaceaVarious forms; background erythema with inflammatory papules and pustules often superimposed; environmental factors often can triggerSyringomaNoninflammatory papules that typically localize to the eyelids and malar cheeks; skin biopsy test results show dilated cysts with tadpole appearanceAdenoma sebaceumSmall waxy papules over the medial cheeks, nose, and forehead; multiple lesions associated with tuberous sclerosis; skin biopsy test results show dermal fibrosis and vascular proliferation and dilatation (angiofibromas). Facial angiofibromas are also a feature of multiple endocrine neoplasia type I and, rarely, Birt-Hogg-Dubé syndrome.[^1]Table 2Causative agents of drug-induced acneiform eruptionsTable 2Class of agentExamplesHormonesCorticosteroids and corticotropinAndrogens and anabolic Steroid medicationsHormonal contraceptive medicationsNeuropsychotherapeutic drugsTricyclic antidepressant medicationsLithiumAntiepileptic drugsAripiprazoleSelective serotonin reuptake inhibitorsVitaminsVitamins B1, B6, and B12Cytostatic drugsDactinomycin (actinomycin D)Immunomodulating moleculesCyclosporineSirolimusAntituberculosis drugsIsoniazidRifampinEthionamideHalogensIodineBromineChlorineTargeted therapiesEpidermal growth factor receptor inhibitorsMultitargeted tyrosine kinase inhibitorsVascular endothelial growth factor inhibitorProteasome inhibitorTumor necrosis factor alfa inhibitorsHistone deacetylase inhibitor[^2]

Further testing {#s0025}
===============

Microbiologic testing {#s0030}
---------------------

*P. acnes* is thought to be an important pathogen in the development of acne. Routine cultures are not done unless gram-negative folliculitis or *Staphylococcus aureus* folliculitis are considered in the differential diagnosis ([@bb1420]).

Gram-negative folliculitis presents as monomorphic eruptive pustules in the perioral, beard, and neck distribution and typically in the setting of prolonged oral tetracycline use ([@bb1420]). Gram-negative folliculitis is caused by gram-negative microbes such as *Klebsiella* and *Serratia* and is treated with isotretinoin. Microbe-directed therapy may be considered given the clinical setting and individual patient characteristics. The American Academy of Dermatology (AAD) 2016 working group on the management of acne vulgaris only recommends microbiologic testing for those who exhibit acne-like lesions that are suggestive of gram-negative folliculitis and not otherwise ([@bb1420]).

Endocrine testing {#s0035}
-----------------

The role of androgens in acne is well established. Endocrine testing is only needed in patients who have other signs or symptoms of hyperandrogenism. The most common cause of increased androgens in adult women is PCOS ([@bb0825]). Clinically, hyperandrogenism can manifest by unwanted hair growth/hirsutism, seborrhea, acne, and/or androgenetic alopecia ([@bb0060]). Significant virilization suggests disorders of severe insulin resistance, androgen-secreting tumors, and androgenic substance abuse ([@bb0060]). A laboratory test panel to screen for PCOS includes free and total testosterone, dehydroepiandrosterone sulfate, androstenedione, luteinizing hormone, and follicle-stimulating hormone ([@bb0060], [@bb0720], [@bb0825], [@bb0835], [@bb0845], [@bb1155], [@bb1320]). The differential diagnosis of PCOS includes thyroid disease, prolactin excess, nonclassical congenital adrenal hyperplasia, and other rare endocrinology disorders ([@bb1420]).

Women who are already prescribed oral contraceptive medications and display additional signs of androgen excess should have similar testing done, although oral contraceptive pills may be beneficial to women with clinical and laboratory findings of hyperandrogenism as well as in women without these findings ([@bb1420]). An endocrinologist should evaluate patients with abnormal hormone levels. The AAD working group only recommends laboratory evaluations for patients who have acne and additional signs of androgen excess ([@bb1420]).

Treatment of acne vulgaris {#s0040}
==========================

[Table 3](#t0015){ref-type="table"} shows the various treatments for patients with AV, along with the strength of recommendations from the AAD working group but modified to include pregnancy and lactation ratings. This review article focuses on topical therapies, systemic antibiotic medications, isotretinoin, and novel therapies under development. We emphasize limiting treatment duration of systemic antibiotic medications in adults with acne and prescribing concomitant and/or maintenance treatment with topical therapy. A more complete discussion on the use of hormonal agents can be found in an article by [@bb1345] entitled "A review of hormone-based therapies for adult acne vulgaris in women," which was also published in the *International Journal of Women's Dermatology*. [Table 4](#t0020){ref-type="table"} shows the AAD working group's treatment algorithm for the management of AV in adolescents and young adults, which requires an adjustment on the basis of patient risk factors, types and sites of acne lesions, and age.Table 3AAD 2016 Working Group strength of recommendations for the management and treatment of patients with acne vulgaris[a](#tf0005){ref-type="table-fn"}Table 3RecommendationStrength of recommendation[b](#tf0010){ref-type="table-fn"}Level of evidence[c](#tf0015){ref-type="table-fn"}FDA classification system pregnancy rating[d](#tf0020){ref-type="table-fn"}Lactation ratingAAP classification systemLactMed[d](#tf0020){ref-type="table-fn"}Topical therapies Benzoyl peroxideAI, IICNot ratedLow risk Topical antibiotic medications (e.g., clindamycin and erythromycin)AI, IIBCompatibleAcceptable Combination of topical antibiotic medications and benzoyl peroxideAI Topical retinoid medications (e.g., tretinoin, adapalene, and tazarotene)AI, IITretinoin -- C\
Adapalene - C\
Tazarotene - XNot ratedLow risk Combination of topical retinoid medications and benzoyl peroxide/topical antibiotic medicationAI, II Azelaic acidAIBNot ratedLow risk DapsoneAI, IICCompatibleAvoid in G6PD deficiency, newborn/premature infants Salicylic acidBIICNot ratedNot ratedSystemic antibiotic medications Tetracyclines (e.g., tetracycline, doxycycline, and minocycline)AI, IIDCompatibleShort-term use acceptable Macrolides (e.g., azithromycin and erythromycin)AIBCompatibleAcceptable Trimethoprim (with or without sulfamethoxazole)BIICCompatibleAvoid in jaundiced, ill, premature infants **Limiting treatment duration and concomitant/maintenance topical therapyAI, II**Hormonal agents Combined oral contraceptive medicationsAIXCompatibleAvoid \< 4 weeks post-partum SpironolactoneBII, IIICCompatibleAppears acceptable FlutamideCIIIDNot ratedNot rated Oral corticosteroid medicationsBIICCompatibleAcceptableIsotretinoin Conventional dosingAI, IIXNot ratedNo recommendation made Low-dose treatment for moderate acneAI, IIXNot ratedNo recommendation made MonitoringBII iPledge enrollment and contraception useAIINovel therapies Minocycline foam Topical nitric oxide-releasing agent Cortexolone 17α-propionate[^3][^4][^5][^6][^7]Table 4American Academy of Dermatology 2016 Working Group treatment algorithm for the management of adolescents and young adults with acne vulgaris[a](#tf0025){ref-type="table-fn"}Table 4MildModerateSevereFirst-line TreatmentBP or topical retinoid\
\
-or-\
\
Topical combination therapy[b](#tf0030){ref-type="table-fn"}\
(BP + antibiotic or retinoid + BP or\
retinoid + BP + antibiotic)Topical combination therapy[b](#tf0030){ref-type="table-fn"}\
(BP + antibiotic or retinoid + BP or\
retinoid + BP + antibiotic)\
\
-or-\
\
Oral antibiotic + topical retinoid + BP\
\
-or-\
\
Oral antibiotic + topical retinoid + BP + topical antibioticOral antibiotic + topical combination therapy[b](#tf0030){ref-type="table-fn"}\
(BP + antibiotic or retinoid + BP or\
retinoid + BP + antibiotic)\
\
-or-\
\
Oral isotretinoinAlternative treatmentAdd topical retinoid or BP (if not on already)\
\
-or-\
\
Consider alternate retinoid\
\
-or-\
\
Consider topical dapsoneConsider alternate combination therapy\
\
-or-\
\
Consider change in oral antibiotic\
\
-or-\
\
Add combined oral contraceptive or oral spironolactone (females)\
\
-or-\
\
Consider oral isotretinoinConsider change in oral antibiotic\
\
-or-\
\
Add combined oral contraceptive or oral spironolactone (females)\
\
-or-\
\
Consider oral isotretinoin[^8][^9][^10]

The treatment of acne is challenging and often chronic, with high rates of failure and numerous choices. A good therapeutic relationship with the patient is important to establish as well as setting realistic treatment goals. Frequent evaluations (i.e., every 8-12 weeks) are important to enable appropriate monitoring, manage adverse effects, and evaluate for medication compliance ([@bb0610]). Patient counseling is critical, especially to establish a time course for medication efficacy and discuss future therapeutic modalities in case of treatment failure or intolerability.

Treatment of acne vulgaris in adult women {#s0045}
=========================================

The central tenets of acne management as displayed in [Table 4](#t0020){ref-type="table"} should be followed in the treatment of adult female patients. However, additional considerations exist that should be kept in mind during treatment. Women over the age of 25 years tend to have high rates of treatment failure ([@bb0610]). Approximately 80% of women fail multiple courses of systemic antibiotic medications and approximately 30% to 40% fail after a course of isotretinoin ([@bb0125], [@bb0445], [@bb0450], [@bb1085]). Suspicion of an underlying endocrinology disorder should be heightened if a recurrence of acne appears shortly after treatment with isotretinoin ([@bb0820]).

Treatment of acne vulgaris during pregnancy and lactation {#s0050}
=========================================================

Women of childbearing potential should also be asked about their plans for reproduction, and treatment should be tailored for safety, whether the patients are actively trying to conceive, pregnant, or lactating ([Table 3](#t0015){ref-type="table"}). Among the physiologic changes of pregnancy is a rise in serum androgen levels ([@bb0150]), which results in increased sebaceous gland activity and often worsening of the acne. Published information on the effects of acne medications on the developing fetus or breastfeeding infant is very limited ([@bb0675]). Pregnancy and lactation are often part of the exclusion criteria in clinical trials; therefore, available information on medication-related teratogenicity and effects on lactation are often derived from case reports and animal studies.

The most widely used pregnancy classification is the U.S. Food and Drug Administration (FDA) assessment system, which stratifies drugs into five risk categories ([Table 5](#t0025){ref-type="table"}). However, this classification system has been criticized for its large focus on animal data and frequent classification of new medications as class B (safe in pregnancy; [@bb0675]) as well as its excessive simplicity and lack of information about the severity and nature of possible side effects on the fetus ([@bb1070]). More recently, the FDA released the Pregnancy and Lactation Labeling Rule, which went into effect on June 30, 2015. The most significant change is the abolishment of pregnancy labeling categories for pharmaceuticals (A, B, C, D, and X), which was replaced with individualized narrative summaries for each medication that include "risks of using a drug during pregnancy and lactation, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy and lactation" ([@bb0265]).Table 5Summary of U.S. Food and Drug Administration categories for medication use in pregnancyTable 5CategoryDescriptionAControlled studies show no risk. Adequate, well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester of pregnancy.BNo evidence of risk in humans. Adequate, well-controlled studies in pregnant women have not shown an increased risk of fetal abnormalities despite adverse findings in animals.\
-or-\
In the absence of adequate human studies, animal studies show no fetal risk. The chance of fetal harm is remote but remains a possibilityCRisk cannot be ruled out. Adequate, well-controlled human studies are lacking and animal studies have shown a risk to the fetus or are lacking as well. There is a chance of fetal harm if the drug is administered during pregnancy but the potential benefits may outweigh the potential riskDPositive evidence of risk. Studies in humans or investigational or post-marketing data have demonstrated fetal risk. Nevertheless, potential benefits from the use of the drug may outweigh the potential risk. For example, the drug may be acceptable if needed in a life-threatening situation or serious disease for which safer drugs cannot be used or are ineffective.XContraindicated in pregnancy. Studies in animals or humans or investigational or post-marketing reports have demonstrated positive evidence of fetal abnormalities or a risk that clearly outweighs any possible benefit to the patientNNo pregnancy category has been assigned

The most commonly used risk classification systems for lactation are from the American Academy of Pediatrics (AAP), [@bb0485], and the recent Drug and Lactation Database (LactMed) that was produced by the National Library of Medicine. For the purposes of this review, the AAP and LactMed rating systems will be discussed.

The AAP system stratifies drugs into three categories: those that should be used with concern; those with unknown effects but may be of concern; and those that are generally compatible with breastfeeding ([@bb0035]). The LactMed system is a peer-reviewed database that provides comprehensive information about drugs that may be used in mothers who breastfeed including serum drug levels, adverse effects on infants, and alternative drugs to consider ([@bb1365]).

Given the lack of data, a lack of unified drug classifications for women who are pregnant or lactating, and the serious risk of teratogenicity, clinicians tend to take a conservative approach to treating acne in this group of women. Additionally, primary practitioners and dermatologists have a popular view that acne is a cosmetic issue, which further leads clinicians to choose less effective treatments or even withhold treatment during pregnancy and lactation ([@bb0675]).

Topical therapies {#s0055}
=================

Topical therapies are considered one of the mainstay treatments for patients with mild-to-moderate acne ([@bb0975]). These topical agents are available over the counter and by prescription. More recently, several topical therapy combinations have been developed to treat patients with acne. The absorption of topical therapies is influenced by many factors, including the amount of agent applied, surface area of the application, length of the application time, frequency of the application, application to broken skin/erosions, choice of vehicle used, and thickness of the stratum corneum ([@bb0935]).

Generally, topical agents are considered safer than oral medications for use in women who are pregnant or lactating because systemic availability of the drug is lower. Some topical medications do not even have a pregnancy category because systemic absorption is generally considered minimal unless use is extensive, intensive, or prolonged ([@bb0935]).

Commonly used topical treatments for patients with acne include benzoyl peroxide (BP), salicylic acid (SA), antibiotic medications, combination antibiotic medications with BP, retinoid medications, retinoid with BP, retinoid with antibiotic medication, azelaic acid, and sulfone agents ([@bb1420]).

Benzoyl peroxide {#s0060}
================

BP is commonly used to treat patients with acne and is available in a variety of strengths (2.5-10%) and formulations (cream, gel, wash, foam, aqueous gel, leave-on, and wash-off). BP is a comedolytic, keratolytic, anti-inflammatory agent with antimicrobial properties. BP is bactericidal mainly against *P. acnes* by the production of reactive oxygen radicals and has not developed resistance ([@bb1290]). The addition of BP to antibiotic therapy enhances results and may reduce antibiotic resistance development ([@bb1420]). Topical BP in varying formulations may be used 1 to 3 times daily as tolerated.

The use of BP is limited by concentration-dependent irritation, staining and bleaching of fabric, and uncommon contact allergy ([@bb1420]). Lower concentrations (2.5-5%), water-based, and wash-off agents may be better tolerated in patients with more sensitive skin ([@bb0950], [@bb1420]).

Some clinicians are reluctant to prescribe BP concurrently with topical tretinoin due to the belief that BP may cause oxidation and degradation of the tretinoin molecule and thereby reduce its effectiveness. However, BP-induced degradation of tretinoin does not apply to all topical tretinoin formulations and multiple studies show the stability of tretinoin concentration and safety when using micronized tretinoin gel (0.05%) in combination with BP ([@bb0285], [@bb0475], [@bb1015], [@bb1330]).

Salicylic acid {#s0065}
==============

SA is a comedolytic agent that is available over the counter in 0.5 to 2% strengths and in both wash-off and leave-on preparations. SA is generally well tolerated by patients, but its efficacy in acne is limited ([@bb1170], [@bb1175]). BP and SA are the most widely used over-the-counter, topical, acne treatments and are often used in combination. SA may be applied 1 to 3 times daily as tolerated. SA has an FDA pregnancy rating of C.

Topical antibiotic medications {#s0070}
==============================

Topical antibiotic medications are thought to accumulate in the follicle and may work through both anti-inflammatory and antibacterial effects ([@bb0955]). Due to increasing antibiotic resistance, monotherapy with topical antibiotic medications in the management of acne is not recommended. Topical antibiotic medications are best used in combination with BP ([@bb1420]). The main topical antibiotic medications are clindamycin and erythromycin.

Topical clindamycin {#s0075}
===================

Clindamycin is available in a gel, lotion, pledget, or topical solution and has been assigned FDA pregnancy category B. The clindamycin 1% solution or gel is currently the preferred topical antibiotic medication ([@bb1000]). The recommended dosing is an application of a thin layer once daily.

Topical erythromycin {#s0080}
====================

Erythromycin is available as a gel, solution, ointment, pledget, or thin film. Oral and topical erythromycin formulations are both classified as FDA category B. Topical erythromycin is less efficacious in patients with acne than clindamycin because of *P. acnes* resistance ([@bb0110], [@bb0690], [@bb0775], [@bb0955], [@bb1165]). Stable, fixed-combination agents are available with erythromycin 3% plus BP 5%, clindamycin 1% plus BP 5%, and clindamycin 1% plus BP 3.75% ([@bb0810], [@bb1020], [@bb1350]). Combination agents may enhance compliance with treatment regimens ([@bb1420]). Topical erythromycin is usually administered 1 to 2 times daily.

Topical retinoid medications {#s0085}
============================

Topical retinoid medications are vitamin A--derivative prescription agents ([@bb0155], [@bb0685], [@bb0850], [@bb1185]). Topical retinoid medications are often used as first-line treatment for patients with mild-to-moderate acne, especially when the acne is mainly comedonal. Retinoid therapy is comedolytic and resolves the precursor microcomedone lesion. Retinoid medications are also anti-inflammatory and work in combination with other topical agents for all acne variants ([@bb1420]). Topical retinoid treatments are the mainstay in the maintenance of clearance after discontinuation of oral therapy ([@bb1420]). The recommended dosing is application of a thin layer once daily.

Three topical retinoid medications are used in the treatment of patients with acne: tretinoin (0.025-0.1% in cream, gel, or microsphere gel vehicles), adapalene (0.1% cream, gel, or lotion and 0.3% gel), and tazarotene (0.05%, 0.1% cream, gel, or foam). Retinoid use is limited by side effects including dryness, peeling, erythema, and irritation, which can be mitigated by reducing the volume used, the frequency of the application, and/or concomitant use of emollients ([@bb1040]). Generally, therapy is initiated best every other day and then increased to daily as tolerated. The proper amount to use (e.g., pea size) is also important, as is ensuring even distribution with a thin layer and avoiding sensitive areas (e.g., eyelids, perioral area, nasal creases, and mucous membranes). With any of the topical retinoid treatments, higher concentrations are more efficacious but have greater side effects ([@bb0215], [@bb0255], [@bb0685]). Additionally, topical retinoid medications increase the risk of photosensitivity so sunscreen lotion should be used concurrently.

Generic formulations of tretinoin are typically not photostable and should be applied in the evening. Coadministration of BP with tretinoin also leads to oxidation and inactivation of tretinoin; therefore, these agents should be applied at different times (i.e., BP in the morning, tretinoin at night). The micronized tretinoin formation as well as adapalene and tazarotene do not have similar restrictions.

Available combination agents that contain retinoid include adapalene 0.1% plus BP 2.5% and adapalene 0.3% plus BP 2.5% gels, which are approved for use in patients older than 9 years. In addition, clindamycin phosphate 1.2% plus tretinoin 0.025% gel is approved for patients older than 12 years of age ([@bb0325], [@bb1450]).

There are conflicting reports on the safety of topical retinoid medications in women who are pregnant or lactating. Isolated cases have been reported of congenital malformations that were temporally associated with the use of these agents ([@bb0055], [@bb0795], [@bb0815], [@bb0980], [@bb1005], [@bb1160]). However, a large observational prospective study of 235 women who were exposed to a topical retinoid during their first trimester were compared with 444 women in the control group and no statistically significant differences in the rates of spontaneous abortions and minor or major birth defects were detected ([@bb1005]). A formal consensus on the safety of topical retinoid medications during pregnancy is lacking ([@bb1375]). Additionally, manufacturers advise that these agents should not be used during pregnancy. Tretinoin and adapalene are classified as FDA pregnancy category C but tazarotene is category X. Patients should be counseled on these pregnancy risks when initiating retinoid treatment if they desire pregnancy.

Azelaic acid {#s0090}
============

Azelaic acid acts as a comedolytic, antimicrobial, and anti-inflammatory agent ([@bb1265]) and is a naturally occurring dicarboxylic acid that is found in whole-grain cereals such as wheat, rye, and barley ([@bb0390]). Azelaic acid should be used with caution in patients with sensitive skin due to side effects that include redness, burning, and irritation.

Azelaic acid should also be used with caution in patients with Fitzpatrick skin types IV or greater because of its potential lightening effect ([@bb0250], [@bb0620], [@bb0665]). However, because of this side effect, azelaic acid is a useful adjunctive in acne treatment because it aids in the treatment of postinflammatory dyspigmentation.

The dosing recommendation is application of a thin film to the affected areas twice daily. Azelaic acid is categorized as FDA pregnancy class B because animal studies have shown no teratogenicity, but data on humans are not available.

Dapsone {#s0095}
=======

Dapsone is a sulfone agent that is available in a 5% gel and used as a twice-daily agent or 7.5% gel used once daily. Data only show modest-to-moderate efficacy in the reduction of inflammatory acne lesions ([@bb0310], [@bb0855]). Dapsone has a poorly understood mechanism in the treatment of patients with acne and its ability to kill *P. acnes* has been studied poorly ([@bb1420]). Similar to other topical antibiotic treatments, dapsone is thought to work as an anti-inflammatory agent. The recommended dosing is application of a thin layer twice daily.

Dapsone should be used cautiously in combination with BP because coapplication may cause reversible, orange-brown discoloration of the skin, which can be brushed or washed off. Systemic absorption of topical dapsone is thought to be minimal so baseline glucose-6-phosphate dehydrogenase testing is not required. Topical dapsone is classified as FDA pregnancy category C.

Other topical agents {#s0100}
====================

The following topical agents lack evidence-based data for their use in patients with acne but have been demonstrated to be effective in clinical practice: sodium sulfacetamide ([@bb0735], [@bb1295], [@bb1300]), sulfur ([@bb0340]), resorcinol ([@bb0340]), aluminum chloride ([@bb0520], [@bb0555]), topical zinc ([@bb0130], [@bb0220]), and niacinamide ([@bb0645], [@bb1180]).

Systemic antibiotic medications {#s0105}
===============================

Oral antibiotic medications are commonly prescribed as second-line therapy for patients with mild-to-moderate acne that is not adequately controlled with topical agents alone and are a mainstay of acne treatment in patients with moderate-to-severe inflammatory acne. Oral antibiotic agents should be used in combination with a topical retinoid and BP if tolerated ([@bb0420], [@bb1285]; ([@bb1415]).

Given the rise in antibiotic resistance, monotherapy with oral antibiotic medications is strongly discouraged ([@bb0960], [@bb1420]). The Centers for Disease Control and Prevention has stressed antibiotic stewardship and limit antibiotic use to the shortest possible duration, ideally 3-4 months ([@bb1420]), to reduce the risk of resistance. Concurrent and continued use with a retinoid or retinoid/BP combination can assist in weaning off the systemic antibiotic ([@bb0420], [@bb0780], [@bb1065], [@bb1275], [@bb1315]).

Limiting systemic antibiotic use may also reduce the risk of inflammatory bowel disease (for tetracyclines; [@bb9000]), pharyngitis (for tetracyclines; [@bb0905]), *C. difficile* infection ([@bb0090], [@bb0175]), and candida vulvovaginitis; however, studies have shown that these associations are limited. Penicillin, erythromycin, and cephalosporin are thought to have the best safety profile during pregnancy ([@bb0515]).

Of note, there is limited evidence on the administration of antibiotic agents and the potential impact on the effectiveness of oral contraceptive pills ([@bb0530]). Although a large epidemiological study that was conducted in the United States showed that there is no association between concomitant antibiotic use and the risk of breakthrough pregnancy among oral contraceptive pill users ([@bb0465]), other studies have shown a potential relationship ([@bb0070], [@bb0075], [@bb0360], [@bb1215]). There are three categories of antibiotic agents that range from those that are likely to reduce the effectiveness of OCPs (rifampin), those that are associated with OCP failure in three or more reported cases (ampicillin, amoxicillin, metronidazole, and tetracycline), and those that were associated with OCP failure in at least one case report (cephalexin, clindamycin, dapsone, erythromycin, griseofulvin, isoniazid, phenoxymethylpenicillin, talampicillin, and trimethoprim; [@bb0945]). A conservative approach is the recommend use of a second form of contraception while taking a systemic antibiotic agent ([@bb1445]), but evidence for this is very limited ([@bb0945]).

Tetracycline class {#s0110}
==================

Tetracycline treatments, which include minocycline, doxycycline, and tetracycline, are considered first-line therapy in patients with moderate-to-severe inflammatory acne except in certain circumstances including pregnancy, age \< 8 years, or known allergy. Tetracycline agents have notable anti-inflammatory effects ([@bb1420]). Pseudotumor cerebri is a rare phenomenon that is associated with the use of tetracycline agents ([@bb1420]).

Tetracycline medications including minocycline and doxycycline are classified as FDA pregnancy category D. Tetracycline agents should not be used during pregnancy because use during the second and third trimester is known to cause discoloration of the teeth and bones. However, there is no firm evidence that first-trimester use is associated with major birth defects ([@bb0675], [@bb0935]). Cases of maternal liver toxicity that is associated with the use of tetracycline agents during the third trimester have been reported ([@bb0490], [@bb1120], [@bb1400]). Although there is a theoretical risk of bone and teeth malformation if tetracycline is administered during lactation, low concentrations of neonatal absorption are expected because of its strong binding with calcium ions in breast milk. Tetracycline is generally considered safe for use during breast feeding ([@bb1240]).

Doxycycline {#s0115}
===========

Doxycycline appears to be effective for patients with AV in the 1.7 to 2.4 mg/kg dose range ([@bb0785]), but for practical purposes, doxycycline is usually administered at 50 to 100 mg twice daily for adult patients with acne. Subantimicrobial dosing of doxycycline (i.e., 20 mg twice daily or 40 mg daily) is also effective in patients with moderate inflammatory acne ([@bb0965], [@bb1325]), which further supports tetracycline's anti-inflammatory properties.

Issues to consider when prescribing doxycycline include the fact that doxycycline is more photosensitizing than minocycline ([@bb1420]) and more frequently associated with gastrointestinal disturbances, especially at higher doses ([@bb0785]). To mitigate these side effects, patients should be counseled to use sunscreen lotion and other photoprotective measures to decrease the risk of sunburns, take doxycycline with a meal or a full glass of water, and not take doxycycline less than 1 hour prior to bedtime. Additionally, absorption is decreased with the concomitant intake of iron and calcium. The hyclate version of doxycycline tends to have greater gastrointestinal side effects compared with the monohydrate form. Doxycycline is primarily metabolized by the liver and can be used safely in most patients with renal disease ([@bb1420]).

Minocycline {#s0120}
===========

Previously, treatment with minocycline was thought to be superior to doxycycline in reducing *P. acnes* ([@bb1265]). However, a recent Cochrane review found that minocycline was effective to treat patients with AV but was not superior to other antibiotic medications ([@bb0400]). Minocycline has been shown to be safe and effective at dose of 1 mg/kg, but no dose response was found for efficacy ([@bb0375], [@bb1420]). For practical purposes, minocycline is generally dosed at 50 to 100 mg twice daily.

Compared with doxycycline, minocycline tends to have lower rates of gastrointestinal side effects but is associated with tinnitus, dizziness, and pigment deposition within the skin, mucous membranes, and teeth. Minocycline-associated pigmentation is more common in patients who take higher doses for longer periods of time ([@bb1420]). Rare, serious, immune-mediated events have also been associated with minocycline including drug-induced hypersensitivity syndrome or a drug reaction with eosinophilia and systemic symptoms, drug-induced lupus, and other hypersensitivity reactions ([@bb0635], [@bb1195], [@bb1220], [@bb1340], [@bb1395]).

Macrolides {#s0125}
==========

Macrolide medications including erythromycin and azithromycin have been used in the treatment of patients with acne but recently have fallen out of favor as first-line treatment. Macrolide agents are considered alternative therapy when traditional antibiotic medications cannot be used. As with tetracycline, macrolide has some anti-inflammatory properties but the specific mechanism of action in acne is unknown.

The most common side effect is gastrointestinal disturbances ([@bb1420]). Macrolide medications occasionally can cause cardiac conduction abnormalities and rarely cause hepatotoxicity ([@bb1420]). Macrolide agents as a class have been classified by AAP as safe during lactation ([@bb0675]).

Erythromycin {#s0130}
============

Erythromycin is the traditional oral antibiotic medication of choice when a systemic antibiotic treatment is needed for acne while a patient is pregnant ([@bb0490], [@bb0680]). Due to increasing bacterial resistance, erythromycin should be combined with a topical preparation such as BP ([@bb0935]). Due to the differences in absorption, 400 mg erythromycin ethyl succinate produces the same serum levels as 250 mg erythromycin base or stearate. For the erythromycin base, dosing ranges from 250 to 500 mg twice daily. For erythromycin ethyl succinate, dosing ranges from 400 to 800 mg twice daily.

Oral erythromycin is classified as FDA pregnancy category B. Erythromycin is more commonly used during pregnancy to treat other infections, which resulted in larger retrospective studies on pregnancy outcomes ([@bb1110]). Although erythromycin is largely considered safe for use during pregnancy, reports of fetal cardiac malformation exist ([@bb0605]) and prolonged use has been associated with hepatotoxicity in 10-15% of pregnant patients ([@bb0490], [@bb0925]).

Azithromycin {#s0135}
============

Azithromycin is an azalide antibiotic agent that is derived from erythromycin ([@bb0935]) and tends to be better tolerated compared with erythromycin ([@bb0675]). Azithromycin has been studied in varying doses (from 3 times a week to 4 days a month) with varying efficacy in patients with AV and all trials used pulse-dosing regimens ([@bb0045], [@bb0100], [@bb0570], [@bb0695], [@bb0880], [@bb1030], [@bb1090], [@bb1420]).

Trial doses have included 500 mg once daily for 4 consecutive days per month for 2 consecutive months ([@bb0065], [@bb1030]), 500 mg once daily for 3 days in the first week followed by 500 mg once weekly until week 10 ([@bb0880]), or 500 mg once daily for 3 consecutive days each week in month 1 followed by 500 mg once daily for 2 consecutive days each week in month 2 and then 500 mg once daily for 1 day each week in month 3 ([@bb0695]). One study from 2005 showed that azithromycin is as effective to treat patients with AV as doxycycline ([@bb0695]). A more recent, randomized, controlled trial that compared treatment with azithromycin 3 days per month to daily doxycycline showed the superiority of doxycycline ([@bb1370]). As with erythromycin, azithromycin is classified as FDA pregnancy category B.

Trimethoprim sulfamethoxazole {#s0140}
=============================

Trimethoprim sulfamethoxazole (TMP/SMX) can be used to treat patients with AV that is recalcitrant to macrolide and tetracycline. Treatment with TMP/SMX and trimethoprim carries serious risks and is used for other infectious disorders, which makes the risk of development of resistance a greater issue. Although a few case reports espouse the efficacy of TMP/SMX in the treatment of patients with acne, one small double-blind study showed that TMP/SMX was as effective as treatment with oxytetracycline ([@bb0585]).

The side effects of TMP/SMX include gastrointestinal upset, photosensitivity, and drug eruptions, the most severe of which is Stevens-Johnson syndrome/toxic epidermal necrolysis ([@bb0370], [@bb1125]). Severe eruptions including Stevens-Johnson syndrome/toxic epidermal necrolysis are more common in patients with HIV.

Rarely, TMP/SMX can cause serious blood dyscrasias such as neutropenia, agranulocytosis, aplastic anemia, and thrombocytopenia, especially if taken as a long-term therapy, which warrants periodic monitoring with a complete blood cell count testing ([@bb1420]). According to the AAD working group, TMP/SMX should be restricted to patients who are unable to tolerate tetracycline agents or in patients who are treatment-resistant ([@bb1420]). The usual dosing for patients with AV is one double-strength tablet twice daily.

TMPS/SMX is classified as FDA pregnancy category C. The use of TMP/SMX during the first trimester of pregnancy can lead to folic acid deficiency, which may in turn result in neural tube defects, structural malformations of the cardiovascular and urinary system, and cleft lip or palate ([@bb0525]). These risks are increased among women who do not use a multivitamin that contains folic acid ([@bb0515]).

Additionally, exposure during the third trimester of pregnancy is small for gestational age infants as well as associated with hyperbilirubinemia ([@bb0525]). Both AAP and LactMed consider TMP/SMX safe for use during lactation except when the baby is premature, has severe jaundice, or has G6PD deficiency, during which there is a higher risk of kernicterus ([@bb0675]).

Penicillin and cephalosporin {#s0145}
============================

Penicillin and cephalosporin are well established as safe for use during pregnancy and lactation ([@bb0490]). However, they are rarely used to treat patients with acne because information with regard to efficacy is sparse. Penicillin and cephalosporin can be used as an alternative to conventional antibiotic medications, especially during pregnancy or with allergies to other classes of antibiotic treatments ([@bb1420]). Side effects include risk of hypersensitivity reactions that range from mild drug eruptions to anaphylaxis and gastrointestinal disturbances (i.e., nausea, diarrhea, and abdominal distention and discomfort; [@bb1420]). The recommended dosing for amoxicillin is 250 mg twice daily up to 500 mg three times daily.

Cephalosporin has in vitro activity against *P. acnes*, but as a class, cephalosporin treatment is hydrophilic and thought to poorly penetrate microcomedones in vivo ([@bb0920]). A retrospective study of 93 patients showed that cephalexin is effective to treat patients with acne; 78% of patients experienced clinical improvement with a dosing regimen of 500 mg twice daily ([@bb0365]).

Isotretinoin {#s0150}
============

Isotretionoin is an important nonhormonal and nonantimicrobial treatment option for adult women with acne ([@bb0435]). Oral isotretinoin is FDA-approved for the treatment of severe recalcitrant AV but can also be used to treat patients with moderate acne that is either treatment-resistant or relapses quickly after discontinuation of oral antibiotic therapy ([@bb0020], [@bb0025], [@bb0135], [@bb0205], [@bb0210], [@bb0625], [@bb0745]). Several studies have shown that isotretinoin effectively decreases sebum production, the number of acne lesions, and acne scarring ([@bb0040], [@bb0200], [@bb0430], [@bb0445], [@bb0450], [@bb0595], [@bb0655], [@bb0725], [@bb0750], [@bb0760], [@bb1035], [@bb1130], [@bb1245], [@bb1250], [@bb1255]). According to the AAD working group, isotretinoin is also indicated for the treatment of patients with moderate inflammatory acne that is either treatment-resistant or produces physical scarring or significant psychosocial distress ([@bb1420]).

Isotretinoin is usually initiated at a starting dose of 0.5 mg/kg/day for the first month and then increased to 1 mg/kg/day as tolerated with a goal of a cumulative dose of between 120 and 150 mg/kg ([@bb0425], [@bb0725], [@bb0755]). In very severe cases, lower initial doses in addition to oral corticosteroid medications may be needed. However, more recent studies have demonstrated that higher cumulative doses that exceed 200 mg/kg may be more effective to reduce the rates of acne relapse and retreatment ([@bb0240], [@bb1440]).

Low-dose isotretinoin (0.25-0.4 mg/kg/day) and lower cumulative dose regimens may be used to minimize the side effects that are associated with systemic retinoid therapy and thereby lead to improved tolerability and increased patient satisfaction ([@bb0020], [@bb0025], [@bb0040], [@bb0205], [@bb0210], [@bb0270], [@bb0740], [@bb1080]). However, intermittent dosing is not as effective as daily dosing and exhibits higher relapse rates ([@bb0020], [@bb0025], [@bb0205], [@bb0210], [@bb0655]). Absorption of isotretinoin is increased with fatty foods and isotretinoin is recommended to be taken with meals ([@bb1260], [@bb1385]). The lidose formulation (Absorica) has absorption profiles that are not dependent on fat intake.

In the treatment of adult women, serious considerations should be given to isotretinoin's potential teratogenicity. In addition, side effects are numerous, including xerosis, cheilitis, xerophthalmia, decreased night vision, vision changes, headache, hepatotoxicity, hypertriglyceridemia, mood changes, bone demineralization, cardiovascular risk factors, possible link to depression/anxiety/mood changes/suicidality, and possible link to inflammatory bowel disease (IBD). With regard to the association of isotretinon with IBD, the position of the AAD is that "current evidence is insufficient to prove either an association of causal relationship between isotretinoin use and IBD" ([@bb1420]). The most prevalent side effects of isotretinoin mimic symptoms of hypervitaminosis A ([@bb1420]). With standard dosing, these side effects resolve after discontinuation of therapy ([@bb1420]).

Data with regard to an evidence-based link between isotretinoin and depression, anxiety, mood changes, or suicidal ideation/suicide is mixed. Although many small case reports and series show that isotretinoin has no negative effect on mood, memory, attention, or executive function ([@bb0030], [@bb0145], [@bb0195], [@bb0225], [@bb0350], [@bb0545], [@bb0590], [@bb0625], [@bb0910], [@bb0985], [@bb0995], [@bb1100], [@bb1105], [@bb1130], [@bb1420]), the FDA presented 40 cases that showed that isotretinoin dechallenge and rechallenge was associated with psychiatric symptoms ([@bb1360]). In the FDA case series, patients recovered after isotretinoin was discontinued and had a recurrence of symptoms after reinitiating isotretinoin. Of these patients, 75% had no reported prior psychiatric history before isotretinoin therapy and the median time to recovery after discontinuation of isotretinoin was 4.5 days, which is consistent with the half-life of isotretinoin and its metabolites. When patients were rechallenged, the time to onset of the psychiatric symptoms was on average shorter, and 10 patients had persistent psychiatric symptoms after isotretinoin discontinuation. As of December 31, 2001, 140 isotretinoin users worldwide have committed suicide while taking isotretinoin or within a few months of discontinuation of treatment and another 257 patients have been hospitalized for severe depression or attempted suicide ([@bb0335]). However, some have argued that the number of reported cases of depression among isotretinoin users is no greater than in the general population ([@bb0710]). The AAD working group recommends that prescribing physicians monitor patients for any indication of depressive symptoms and educate patients on the potential risks of treatment with isotretinoin.

Laboratory test result monitoring for patients on isotretinoin varies widely among practitioners. Serum cholesterol, triglycerides, and transaminases are known to increase in some patients who take oral isotretinoin ([@bb0115], [@bb0275], [@bb1430]). Routine monitoring of serum lipid profiles and liver function studies are recommended to be done regularly but the interval varies ([@bb0115], [@bb0715], [@bb0730], [@bb0930], [@bb1430]). Some practitioners monitor laboratory test results monthly, but others only check at baseline and after dosing changes.

[@bb0500] recommend that in healthy patients with normal baseline lipid panel and liver function test results, repeated studies should be performed after 2 months of isotretinoin therapy. If the findings are normal, no further testing may be required. The AAD working group did not find any evidence-based reason to warrant routine monitoring of complete blood cell counts ([@bb1420]). Pregnancy testing is required for female patients of childbearing potential at baseline, monthly during therapy, and 1 month after completion of isotretinoin treatment.

The use of oral isotretinoin during pregnancy is absolutely contraindicated (FDA pregnancy category X) due to its known severe teratogenicity including craniofacial, cardiac, and thymic malformations ([@bb0715]). As a result of these serious effects, the manufacturers of oral isotretinoin have developed pregnancy prevention programs where preferably two forms of contraception are recommended ([@bb0440]). Currently, the United States and United Kingdom require enrollment in these pregnancy prevention programs to receive oral isotretinoin.

In the United States, the FDA established the iPLEDGE program in 2006. Dermatologists should counsel women that they should not become pregnant 1 month before, during, or within 1 month after completion of isotretinoin therapy. However, in a recent survey study of women who were sexually active during isotretinoin therapy, 29% admitted to noncompliance with the iPLEDGE pregnancy prevention requirements ([@bb0235]).

Miscellaneous and adjuvant therapies {#s0155}
====================================

The following therapies have limited evidence for their efficacy in the treatment of patients with AV. However, these treatments may improve patients' appearance and be helpful as part of an overall AV treatment regimen. Some of these modalities may be helpful to treat acne scarring as well. These treatments include comedo extraction ([@bb0935], [@bb1420]), cryotherapy ([@bb0385]), electrocauterization ([@bb0385]), chemical peels ([@bb0320], [@bb0460], [@bb0560], [@bb0630], [@bb0765], [@bb0935], [@bb1095], [@bb1420]; including glycolic acid [@bb0050], [@bb0460], [@bb0560], SA [@bb0765], and retinoic acid [@bb1095]), microdermabrasion ([@bb0615], [@bb0630], [@bb0800], [@bb1095], [@bb1270]), laser treatment ([@bb1420]; including pulsed dye, potassium titanyl phosphate, fractionated CO~2,~ fractionated and nonfractionated infrared, radiofrequency, and intense pulsed light), photodynamic therapy ([@bb0085], [@bb0415], [@bb0675], [@bb0860], [@bb0975], [@bb1055], [@bb1115], [@bb1135], [@bb1380], [@bb1420] including blue-violet light phototherapy and red light phototherapy), narrow-band ultraviolet B phototherapy ([@bb0935], [@bb1115], [@bb1435]), intralesional triamcinolone acetonide ([@bb0770], [@bb1060]), surgical techniques ([@bb0580], [@bb1095], [@bb1140] including punch excision and subcision), and filler ([@bb0580], [@bb1140]).

Complementary and alternative therapies {#s0160}
=======================================

Many patients wish to use more natural treatments and may look to herbal and alternative agents for treatment. Although most of these agents are generally well tolerated, there are limited data with regard to efficacy and safety. Additionally, the specific ingredients, concentrations, and potential adulteration with other unwanted chemicals is not well regulated and sometimes cannot be confirmed. These complementary and alternative therapies include tea tree oil ([@bb0095], [@bb0140], [@bb0345], [@bb0495], [@bb1190]), niacinamide ([@bb0305], [@bb0385], [@bb0410], [@bb0970]), ayurvedic compounds ([@bb0705], [@bb1010]), barberry extract ([@bb0380]), gluconolactone ([@bb0550]), antioxidant agents ([@bb1145]), zinc ([@bb0315], [@bb0470], [@bb0935], [@bb0975], [@bb1145], [@bb1265]), probiotic treatments ([@bb0600]), fish oil ([@bb0640]), green tea ([@bb0405], [@bb0875], [@bb1425]), basil oil ([@bb0260]), copaiba oil ([@bb0260]), minerals ([@bb0470], [@bb0885], [@bb1025]), resveratrol ([@bb0295], [@bb0355], [@bb1210]), rose water (rosa damascena; [@bb0480]), seaweed ([@bb0170], [@bb0205], [@bb0210]), taurine bromamine ([@bb0890], [@bb0895], [@bb0900]), dietary modification ([@bb0005], [@bb0010], [@bb0120], [@bb0290], [@bb0575], [@bb1265], [@bb1420]), biofeedback-assisted relaxation ([@bb0540]), cognitive imagery ([@bb0540]), and acupuncture ([@bb0650]).

Other complementary and alternative medicines ([@bb0385]) include *Achillea millefolium*, amaranth, antimicrobial peptides, arnica, asparagus, bay, benzoin, birch, bittersweet nightshade, black cumin, black walnut, borage, Brewer's yeast, burdock root, calendula, celandine, chamomile, chaste tree, *Commiphora mukul*, capaiba oil, coriander, cucumber, duckweed, DuZhong extract, English walnut, *Eucalyptus dives*, fresh lemon, garlic, geranium, grapefruit seeds, jojoba oil, juniper twig, labrador tea, lemongrass, lemon, neem, oak bark, onion, orange peel, orange, Oregon grape root, patchouli, pea, petitgrain, pine, pomegranate rind extract, poplar, pumpkin, rose myrtle, rhubarb, rosemary, rue, safflower oil, sandalwood, soapwort, *Sophora flavescens*, specific antibodies, stinging nettle, sunflower oil, *Taraxacum officinale,* thyme, turmeric, vinegar, vitex, witch hazel, *Withania somnifera*, and yerba mate extract.

Novel therapies {#s0165}
===============

New therapies to treat patients with AV continue to be developed. The newest agents include minocycline foam, topical nitric oxide-releasing agent, and cortexolone 17α-propionate. Many of these new therapies are in various stages of testing, and although the ultimate efficacy is difficult to predict, preliminary studies show promising results.

Minocycline foam {#s0170}
================

Oral minocycline has been shown to be effective in the treatment of patients with AV; however, systemic side effects including abnormal mucocutaneous pigmentation and autoimmune reactions may limit its use ([@bb0660], [@bb1220]). A recent phase 2, prospective, multicenter, randomized, double-blind, dose finding study on topical minocycline 4% foam was conducted and showed a significant reduction from baseline in lesion count versus vehicle at 12 weeks for both inflammatory (71.1% vs. 50.5%; *p* = 0.0001) and noninflammatory lesions (72.7% vs. 56.5%; *p* = 0.0197; [@bb1200]). The significant reduction in lesions were observed as early as week 3 and persisted until the end of the study at week 12. Treatment was well tolerated and safe with no drug-related systemic side effects or serious adverse events. Minocycline 4% foam will be further evaluated in phase 3 trials ([@bb1200]).

Topical nitric-oxide {#s0175}
====================

*P. acnes* is known to induce the production of interleukin-1 cytokines and contribute to the pathogenesis of acne. Nitric oxide (NO) has been shown to have broad-spectrum antimicrobial, wound-healing, and immunomodulatory properties ([@bb0395], [@bb0915], [@bb1075]). [@bb1075] showed that *P. acnes* is highly sensitive to NO and human keratinocyte, monocyte, and embryonic zebra fish assays did not reveal cytotoxicity.

In a recent phase 2, randomized, double-blind, placebo-controlled, three-armed study, a topical NO-releasing drug at 1% and 4% had a significantly greater mean percent reduction in noninflammatory lesions and patients who were treated with the 4% concentration had a significantly greater mean percent reduction in inflammatory lesion count at week 12 ([@bb0080]). Both concentrations were safe and well-tolerated by patients.

Topical cortexolone 17α-propionate 1% cream {#s0180}
===========================================

Systemic anti-androgens such as spironolactone and combination oral contraceptive medications can be used in the effective treatment of patients with AV ([@bb0675], [@bb0935], [@bb1310], [@bb1420]). However, systemic use of anti-androgens is limited to women who wish to conceive or have other endocrine disorders or contraindications ([@bb0185]). A topical anti-androgen treatment has not been made available for use to date.

Cortexolone 17α-propionate is a steroidal antiandrogen agent that has strong antiandrogen activity and mild anti-inflammatory properties ([@bb0180]). Cortexolone 17α-propionate competitively inhibits endogenous androgen binding at the human androgen receptor level without inhibiting the skin 5α-reductase ([@bb0180], [@bb1335]). The agent is quickly metabolized once it penetrates the epidermis and frees inactive cortexolone; therefore, cortexolone 17α-propionate does not have systemic antiandrogenic effects ([@bb1335]).

In a pilot randomized, double-blind, comparative study of cortexolone 17α-propionate versus placebo versus tretinoin 0.05% cream, cortexolone 17α-propionate 1% cream was well tolerated by patients and performed significantly better than placebo with regard to reductions in total lesion count, inflammatory lesion count, and acne severity index. Cortexolone 17α-propionate 1% cream was also clinically more effective than tretinoin 0.05% cream but this difference was not statistically significant.

Conclusions {#s0185}
===========

A myriad of treatment choices is available to treat adult female patients with acne. Treatment options should be tailored to the individual patient with considerations for the patient's preferences, tolerability of the agent, and psychosocial factors. A relatively limited number of options are available for the management of acne during pregnancy and lactation. However, the level of evidence on the safety of any therapies during pregnancy and lactation is low. Novel agents continue to be developed to treat patients with AV, which will further enhance the clinician's care of patients with this impactful and prevalent disease.
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